Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 8/20 | 0.53 |
| ▸ | RPS6KA3 | P51812 | 8/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7113135 | 0.90 | SLC22A12 (0.48) | SLC22A12RPS6KA3PTGS2CYP11B1CYP11B2 | |
| SCHEMBL6728189 | 0.87 | SLC22A12 (0.52) | SLC22A12RPS6KA3PTGS2CYP11B1CYP11B2 | |
| SCHEMBL6735012 | 0.87 | SLC22A12 (0.54) | SLC22A12RPS6KA3PTGS2CYP11B1CYP11B2 | |
| SCHEMBL7537280 | 0.86 | RPS6KA3 (0.58) | SLC22A12RPS6KA3PTGS2MAPK14 | |
| SCHEMBL7114976 | 0.85 | SLC22A12 (0.47) | SLC22A12RPS6KA3PTGS2CYP11B1CYP11B2 | |
| SCHEMBL7041361 | 0.85 | SLC22A12 (0.44) | SLC22A12RPS6KA3PTGS2CYP11B1CYP11B2 | |
| SCHEMBL7045230 | 0.85 | RPS6KA3 (0.57) | SLC22A12RPS6KA3PTGS2 | |
| SCHEMBL7546134 | 0.85 | RPS6KA3 (0.61) | SLC22A12RPS6KA3PTGS2 | |
| SCHEMBL7541466 | 0.85 | RPS6KA3 (0.48) | SLC22A12RPS6KA3PTGS2 | |
| SCHEMBL7111676 | 0.85 | PTGS2 (0.49) | SLC22A12RPS6KA3PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296971-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
| WO-2001081332-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | SLC22A12 4145/4885RPS6KA3 1119/4885PTGS2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.